A Prospective and Retrospective Clinical Controlled Observation of Chinese Herbal Decoction (SMLJ01) for Type 1 Gastric Neuroendocrine Tumors
Introduction: Type 1 gastric neuroendocrine tumors (g-NETs) have a good prognosis but a high recurrence rate. Aim: To observe the clinical efficacy of the treatment of type 1 g-NETs with the Chinese herbal decoction SMLJ01. Materials and Methods: A prospective and retrospective, clinical, controlled...
| Main Authors: | , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
SAGE Publishing
2020-10-01
|
| Series: | Integrative Cancer Therapies |
| Online Access: | https://doi.org/10.1177/1534735420958488 |
| _version_ | 1818935088646193152 |
|---|---|
| author | Yingying Chen MD Deng Han MD Jiqing Zhu MD Jie Chen MD, PhD Haiyi Hu MD, PhD Dou Dou MD Xin Wang MD Bing Yuan MD Chao Wang MD, PhD Zhirong Qi MD, PhD Xinran Zhang PhD Jixi Liu MD Jie Luo MD Huangying Tan MD, PhD |
| author_facet | Yingying Chen MD Deng Han MD Jiqing Zhu MD Jie Chen MD, PhD Haiyi Hu MD, PhD Dou Dou MD Xin Wang MD Bing Yuan MD Chao Wang MD, PhD Zhirong Qi MD, PhD Xinran Zhang PhD Jixi Liu MD Jie Luo MD Huangying Tan MD, PhD |
| author_sort | Yingying Chen MD |
| collection | DOAJ |
| description | Introduction: Type 1 gastric neuroendocrine tumors (g-NETs) have a good prognosis but a high recurrence rate. Aim: To observe the clinical efficacy of the treatment of type 1 g-NETs with the Chinese herbal decoction SMLJ01. Materials and Methods: A prospective and retrospective, clinical, controlled observation was conducted in 4 Chinese centers from 2012 to 2019. Patients with type 1 g-NETs were nonrandomly divided into treatment and control groups after endoscopic treatment based on herbal treatment administered according to their wishes. The treatment group received oral SMLJ01, with follow-up every 6 to 12 months, while the control group received follow-up alone. Patient follow-up (via telephone) from 2012 to 2017 was mainly retrospective. All patients after 2017 were followed prospectively. The recurrence times and rates were compared after treatment for at least 6 months. Symptom improvements were evaluated in the treatment group. The follow-up ended on October 31, 2019. Results: During a median follow-up of 22 months (range: 2-86 months), the survival rate was 100%, and no metastases occurred. Twenty-one of the 82 treated patients (25.6%) had recurrence after a median of 22 months, and 22 of the 54 control patients (40.7%) had recurrence after a median of 8 months ( P = .063). The Kaplan-Meier curve analysis showed that the patients in the treatment group had a significantly longer median recurrence-free survival (RFS) time than those in the control group ( P = .001). The risk of recurrence in the treatment group was 0.38 relative to that in the control group (95% CI: 0.20-0.70). The symptom score of the patients after taking Chinese medicine was 19.5 (10.3, 28.0), which was significantly lower than before treatment (31.5 (19.3, 38.0)). The difference was statistically significant ( P < .01). Conclusion: SMLJ01, with the effects of soothing the liver, strengthening the spleen, increasing acid and harmonizing the stomach, may help reduce the recurrence rate, relieve symptoms and prolong the recurrence time in patients with type 1 g-NETs and is worthy of evaluation with further randomized research with large sample sizes and longer follow-up periods. |
| first_indexed | 2024-12-20T05:14:37Z |
| format | Article |
| id | doaj.art-b85f4446288e420c93ac334dfada740f |
| institution | Directory Open Access Journal |
| issn | 1534-7354 1552-695X |
| language | English |
| last_indexed | 2024-12-20T05:14:37Z |
| publishDate | 2020-10-01 |
| publisher | SAGE Publishing |
| record_format | Article |
| series | Integrative Cancer Therapies |
| spelling | doaj.art-b85f4446288e420c93ac334dfada740f2022-12-21T19:52:12ZengSAGE PublishingIntegrative Cancer Therapies1534-73541552-695X2020-10-011910.1177/1534735420958488A Prospective and Retrospective Clinical Controlled Observation of Chinese Herbal Decoction (SMLJ01) for Type 1 Gastric Neuroendocrine TumorsYingying Chen MD0Deng Han MD1Jiqing Zhu MD2Jie Chen MD, PhD3Haiyi Hu MD, PhD4Dou Dou MD5Xin Wang MD6Bing Yuan MD7Chao Wang MD, PhD8Zhirong Qi MD, PhD9Xinran Zhang PhD10Jixi Liu MD11Jie Luo MD12Huangying Tan MD, PhD13China-Japan Friendship Hospital, Beijing, ChinaChina-Japan Friendship Hospital, Beijing, ChinaCancer Hospital Chinese Academy of Medical Sciences, Beijing, ChinaThe First Affiliated Hospital, Sun Yat-sen University, Guangzhou, Guangdong, ChinaBeijing Friendship Hospital, Capital Medical University; National Clinical Research Center for Digestive Diseases; Beijing Digestive Disease Center; Beijing Key Laboratory for Precancerous Lesion of Digestive Diseases, Beijing, ChinaChina-Japan Friendship Hospital, Beijing, ChinaChina-Japan Friendship Hospital, Beijing, ChinaChina-Japan Friendship Hospital, Beijing, ChinaChina-Japan Friendship Hospital, Beijing, ChinaChina-Japan Friendship Hospital, Beijing, ChinaChina-Japan Friendship Hospital, Beijing, ChinaChina-Japan Friendship Hospital, Beijing, ChinaChina-Japan Friendship Hospital, Beijing, ChinaChina-Japan Friendship Hospital, Beijing, ChinaIntroduction: Type 1 gastric neuroendocrine tumors (g-NETs) have a good prognosis but a high recurrence rate. Aim: To observe the clinical efficacy of the treatment of type 1 g-NETs with the Chinese herbal decoction SMLJ01. Materials and Methods: A prospective and retrospective, clinical, controlled observation was conducted in 4 Chinese centers from 2012 to 2019. Patients with type 1 g-NETs were nonrandomly divided into treatment and control groups after endoscopic treatment based on herbal treatment administered according to their wishes. The treatment group received oral SMLJ01, with follow-up every 6 to 12 months, while the control group received follow-up alone. Patient follow-up (via telephone) from 2012 to 2017 was mainly retrospective. All patients after 2017 were followed prospectively. The recurrence times and rates were compared after treatment for at least 6 months. Symptom improvements were evaluated in the treatment group. The follow-up ended on October 31, 2019. Results: During a median follow-up of 22 months (range: 2-86 months), the survival rate was 100%, and no metastases occurred. Twenty-one of the 82 treated patients (25.6%) had recurrence after a median of 22 months, and 22 of the 54 control patients (40.7%) had recurrence after a median of 8 months ( P = .063). The Kaplan-Meier curve analysis showed that the patients in the treatment group had a significantly longer median recurrence-free survival (RFS) time than those in the control group ( P = .001). The risk of recurrence in the treatment group was 0.38 relative to that in the control group (95% CI: 0.20-0.70). The symptom score of the patients after taking Chinese medicine was 19.5 (10.3, 28.0), which was significantly lower than before treatment (31.5 (19.3, 38.0)). The difference was statistically significant ( P < .01). Conclusion: SMLJ01, with the effects of soothing the liver, strengthening the spleen, increasing acid and harmonizing the stomach, may help reduce the recurrence rate, relieve symptoms and prolong the recurrence time in patients with type 1 g-NETs and is worthy of evaluation with further randomized research with large sample sizes and longer follow-up periods.https://doi.org/10.1177/1534735420958488 |
| spellingShingle | Yingying Chen MD Deng Han MD Jiqing Zhu MD Jie Chen MD, PhD Haiyi Hu MD, PhD Dou Dou MD Xin Wang MD Bing Yuan MD Chao Wang MD, PhD Zhirong Qi MD, PhD Xinran Zhang PhD Jixi Liu MD Jie Luo MD Huangying Tan MD, PhD A Prospective and Retrospective Clinical Controlled Observation of Chinese Herbal Decoction (SMLJ01) for Type 1 Gastric Neuroendocrine Tumors Integrative Cancer Therapies |
| title | A Prospective and Retrospective Clinical Controlled Observation of Chinese Herbal Decoction (SMLJ01) for Type 1 Gastric Neuroendocrine Tumors |
| title_full | A Prospective and Retrospective Clinical Controlled Observation of Chinese Herbal Decoction (SMLJ01) for Type 1 Gastric Neuroendocrine Tumors |
| title_fullStr | A Prospective and Retrospective Clinical Controlled Observation of Chinese Herbal Decoction (SMLJ01) for Type 1 Gastric Neuroendocrine Tumors |
| title_full_unstemmed | A Prospective and Retrospective Clinical Controlled Observation of Chinese Herbal Decoction (SMLJ01) for Type 1 Gastric Neuroendocrine Tumors |
| title_short | A Prospective and Retrospective Clinical Controlled Observation of Chinese Herbal Decoction (SMLJ01) for Type 1 Gastric Neuroendocrine Tumors |
| title_sort | prospective and retrospective clinical controlled observation of chinese herbal decoction smlj01 for type 1 gastric neuroendocrine tumors |
| url | https://doi.org/10.1177/1534735420958488 |
| work_keys_str_mv | AT yingyingchenmd aprospectiveandretrospectiveclinicalcontrolledobservationofchineseherbaldecoctionsmlj01fortype1gastricneuroendocrinetumors AT denghanmd aprospectiveandretrospectiveclinicalcontrolledobservationofchineseherbaldecoctionsmlj01fortype1gastricneuroendocrinetumors AT jiqingzhumd aprospectiveandretrospectiveclinicalcontrolledobservationofchineseherbaldecoctionsmlj01fortype1gastricneuroendocrinetumors AT jiechenmdphd aprospectiveandretrospectiveclinicalcontrolledobservationofchineseherbaldecoctionsmlj01fortype1gastricneuroendocrinetumors AT haiyihumdphd aprospectiveandretrospectiveclinicalcontrolledobservationofchineseherbaldecoctionsmlj01fortype1gastricneuroendocrinetumors AT doudoumd aprospectiveandretrospectiveclinicalcontrolledobservationofchineseherbaldecoctionsmlj01fortype1gastricneuroendocrinetumors AT xinwangmd aprospectiveandretrospectiveclinicalcontrolledobservationofchineseherbaldecoctionsmlj01fortype1gastricneuroendocrinetumors AT bingyuanmd aprospectiveandretrospectiveclinicalcontrolledobservationofchineseherbaldecoctionsmlj01fortype1gastricneuroendocrinetumors AT chaowangmdphd aprospectiveandretrospectiveclinicalcontrolledobservationofchineseherbaldecoctionsmlj01fortype1gastricneuroendocrinetumors AT zhirongqimdphd aprospectiveandretrospectiveclinicalcontrolledobservationofchineseherbaldecoctionsmlj01fortype1gastricneuroendocrinetumors AT xinranzhangphd aprospectiveandretrospectiveclinicalcontrolledobservationofchineseherbaldecoctionsmlj01fortype1gastricneuroendocrinetumors AT jixiliumd aprospectiveandretrospectiveclinicalcontrolledobservationofchineseherbaldecoctionsmlj01fortype1gastricneuroendocrinetumors AT jieluomd aprospectiveandretrospectiveclinicalcontrolledobservationofchineseherbaldecoctionsmlj01fortype1gastricneuroendocrinetumors AT huangyingtanmdphd aprospectiveandretrospectiveclinicalcontrolledobservationofchineseherbaldecoctionsmlj01fortype1gastricneuroendocrinetumors AT yingyingchenmd prospectiveandretrospectiveclinicalcontrolledobservationofchineseherbaldecoctionsmlj01fortype1gastricneuroendocrinetumors AT denghanmd prospectiveandretrospectiveclinicalcontrolledobservationofchineseherbaldecoctionsmlj01fortype1gastricneuroendocrinetumors AT jiqingzhumd prospectiveandretrospectiveclinicalcontrolledobservationofchineseherbaldecoctionsmlj01fortype1gastricneuroendocrinetumors AT jiechenmdphd prospectiveandretrospectiveclinicalcontrolledobservationofchineseherbaldecoctionsmlj01fortype1gastricneuroendocrinetumors AT haiyihumdphd prospectiveandretrospectiveclinicalcontrolledobservationofchineseherbaldecoctionsmlj01fortype1gastricneuroendocrinetumors AT doudoumd prospectiveandretrospectiveclinicalcontrolledobservationofchineseherbaldecoctionsmlj01fortype1gastricneuroendocrinetumors AT xinwangmd prospectiveandretrospectiveclinicalcontrolledobservationofchineseherbaldecoctionsmlj01fortype1gastricneuroendocrinetumors AT bingyuanmd prospectiveandretrospectiveclinicalcontrolledobservationofchineseherbaldecoctionsmlj01fortype1gastricneuroendocrinetumors AT chaowangmdphd prospectiveandretrospectiveclinicalcontrolledobservationofchineseherbaldecoctionsmlj01fortype1gastricneuroendocrinetumors AT zhirongqimdphd prospectiveandretrospectiveclinicalcontrolledobservationofchineseherbaldecoctionsmlj01fortype1gastricneuroendocrinetumors AT xinranzhangphd prospectiveandretrospectiveclinicalcontrolledobservationofchineseherbaldecoctionsmlj01fortype1gastricneuroendocrinetumors AT jixiliumd prospectiveandretrospectiveclinicalcontrolledobservationofchineseherbaldecoctionsmlj01fortype1gastricneuroendocrinetumors AT jieluomd prospectiveandretrospectiveclinicalcontrolledobservationofchineseherbaldecoctionsmlj01fortype1gastricneuroendocrinetumors AT huangyingtanmdphd prospectiveandretrospectiveclinicalcontrolledobservationofchineseherbaldecoctionsmlj01fortype1gastricneuroendocrinetumors |